Cellular thermal shift assay for the identification of drug-target interactions in the Plasmodium falciparum proteome
- PMID: 32341577
- DOI: 10.1038/s41596-020-0310-z
Cellular thermal shift assay for the identification of drug-target interactions in the Plasmodium falciparum proteome
Abstract
Despite decades of research, little is known about the cellular targets and the mode of action of the vast majority of antimalarial drugs. We recently demonstrated that the cellular thermal shift assay (CETSA) protocol in its two variants: the melt curve and the isothermal dose-response, represents a comprehensive strategy for the identification of antimalarial drug targets. CETSA enables proteome-wide target screening for unmodified antimalarial compounds with undetermined mechanisms of action, providing quantitative evidence about direct drug-protein interactions. The experimental workflow involves treatment of P. falciparum-infected erythrocytes with a compound of interest, heat exposure to denature proteins, soluble protein isolation, enzymatic digestion, peptide labeling with tandem mass tags, offline fractionation, and liquid chromatography-tandem mass spectrometry analysis. Methodological optimizations necessary for the analysis of this intracellular parasite are discussed, including enrichment of parasitized cells and hemoglobin depletion strategies to overcome high hemoglobin abundance in the host red blood cells. We outline an effective data processing workflow using the mineCETSA R package, which enables prioritization of drug-target candidates for follow-up studies. The entire protocol can be completed within 2 weeks.
Similar articles
-
A proteomic glimpse into the effect of antimalarial drugs on Plasmodium falciparum proteome towards highlighting possible therapeutic targets.Pathog Dis. 2021 Jan 9;79(1):ftaa071. doi: 10.1093/femspd/ftaa071. Pathog Dis. 2021. PMID: 33202000 Review.
-
Multi-omic Characterization of the Mode of Action of a Potent New Antimalarial Compound, JPC-3210, Against Plasmodium falciparum.Mol Cell Proteomics. 2020 Feb;19(2):308-325. doi: 10.1074/mcp.RA119.001797. Epub 2019 Dec 13. Mol Cell Proteomics. 2020. PMID: 31836637 Free PMC article.
-
A chemical proteomics approach for the search of pharmacological targets of the antimalarial clinical candidate albitiazolium in Plasmodium falciparum using photocrosslinking and click chemistry.PLoS One. 2014 Dec 3;9(12):e113918. doi: 10.1371/journal.pone.0113918. eCollection 2014. PLoS One. 2014. PMID: 25470252 Free PMC article.
-
Identification of Antimalarial Compounds That Require CLAG3 for Their Uptake by Plasmodium falciparum-Infected Erythrocytes.Antimicrob Agents Chemother. 2019 Apr 25;63(5):e00052-19. doi: 10.1128/AAC.00052-19. Print 2019 May. Antimicrob Agents Chemother. 2019. PMID: 30782998 Free PMC article.
-
Advances in omics-based methods to identify novel targets for malaria and other parasitic protozoan infections.Genome Med. 2019 Oct 22;11(1):63. doi: 10.1186/s13073-019-0673-3. Genome Med. 2019. PMID: 31640748 Free PMC article. Review.
Cited by
-
9-Butyl-Harmol Exerts Antiviral Activity against Newcastle Disease Virus through Targeting GSK-3β and HSP90β.J Virol. 2023 Mar 30;97(3):e0198422. doi: 10.1128/jvi.01984-22. Epub 2023 Mar 6. J Virol. 2023. PMID: 36877059 Free PMC article.
-
The novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma.Br J Cancer. 2023 Dec;129(12):1915-1929. doi: 10.1038/s41416-023-02464-y. Epub 2023 Oct 26. Br J Cancer. 2023. PMID: 37884683 Free PMC article.
-
CETSA MS Profiling for a Comparative Assessment of FDA-Approved Antivirals Repurposed for COVID-19 Therapy Identifies TRIP13 as a Remdesivir Off-Target.SLAS Discov. 2021 Mar;26(3):336-344. doi: 10.1177/2472555220973597. Epub 2020 Nov 18. SLAS Discov. 2021. PMID: 33208020 Free PMC article.
-
Cellular Target Deconvolution of Small Molecules Using a Selection-Based Genetic Screening Platform.ACS Cent Sci. 2022 Oct 26;8(10):1424-1434. doi: 10.1021/acscentsci.2c00609. Epub 2022 Sep 22. ACS Cent Sci. 2022. PMID: 36313155 Free PMC article.
-
AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells.J Immunother Cancer. 2023 May;11(5):e006483. doi: 10.1136/jitc-2022-006483. J Immunother Cancer. 2023. PMID: 37164450 Free PMC article.
References
-
- World Health Organization. World Malaria Report 2019 (2019).
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
